Researchers at Chinese Academy of Sciences have used HoloMonitor®technology from PHI to investigate cell behavior when Earth’s magnetic field is eliminated. The findings were recently published in Scientific Reports – an online journal published by Nature Publishing Group.
One of the cell laboratories at Kyushu University in Japan has ordered two HoloMonitor® instruments to complement the instrument previously purchased by the laboratory. The university is one of the seven imperial universities which today form Japan’s prestigious national universities.
Cells cultivated on nanowires, imaged by HoloMonitor Researchers at Lund University have used HoloMonitor® technology from Phase Holographic Imaging to investigate the behavior of cells when cultivated on nanowires. The findings were recently published in Scientific Reports – anonline journal published by Nature Publishing Group.
PHI and Boston Children’s Hospital – a Harvard Medical School teaching hospital – have signed an agreement to evaluate PHI’s HoloMonitor®technology for applications in cell-based cancer research.
Prior to the company’s IPO in early 2014, three market acceptance goals were set out to be achieved by the end of 2015: 50 units in operation at customers and key opinion leaders, collaboration agreements with 8 key opinion leaders and the company’s main product HoloMonitor® M4 shall be manufactured in series production.
Upon completion of an extensive evaluation in early September one of the top pharmaceutical companies in the world has decided to acquire two HoloMonitor® instruments. The ordered configuration is an automated version of the HoloMonitor platform.
Ovarian cancer is one of the deadliest forms of cancer. Researchers at the Center of Excellence for Holographic Imaging at Northeastern University in Boston have used HoloMonitor technology to study how the immune system can be stimulated to fight this deadly cancer form. The research results have been published in Journal of Clinical & Cellular Immunology.
Florida International University (FIU) and PHI have entered a collaboration agreement. To determine the scope of a long-term collaboration, PHI will initially provide FIU with a HoloMonitor instrument during 4 months. The instrument will be used to characterize breast cancer stem cells. Additional information about the collaboration has been published on the university’s website, breakthroughs.fiu.edu.
PHI has entered into a collaboration agreement with University of California, San Francisco (UCSF) to accelerate ongoing skin cancer research at UCSF. Under the 11 month agreement, PHI will provide a HoloMonitor® M4.5 with a motorized stage to supplement the instrument which UCSF purchased previously for preclinical research in the field. “A key strategic goal for
Researchers at University of Pannonia in Hungary recently published a scientific study where HoloMonitor technology from Phase Holographic Imaging (PHI) is used to study cell growth on nanostructures. The study confirms that HoloMonitor technology has a unique potential to become an important tool for investigating cellular behavior on nanostructures under the influence of pharmaceuticals. In
Phase Holographic Imaging PHI AB
Scheelevägen 22
223 63 Lund
Sweden
Scheelevägen 22
223 63 Lund
Sweden
info@phiab.se
support@phiab.se
| VAT: | SE556542781101 |
| ISIN: | SE0005504636 |
| LEI: | 549300JZR79QYESM6296 |
HoloMonitor® and HoloMetrics® are registered trademarks. Copyright © 2012-2018, Phase Holographic Imaging PHI AB.
Privacy policy
